tuberculosis. Respiratory tuberculosis, bacteriologically and histologically confirmed
Conditions
Interventions
Intervention 1: Intervention group (cessation consultation and pharmacotherapy ): smokers patients with pulmonary tuberculosis who are under Tb DOTS Treatment that recieve smoke cessation program
strongly and clearly advice to quit smoking, given the benefits of cessation and linking it with their current disease status by trained physician during their TB treatment in the first visit. Inter
Treatment - Drugs
Behavior
Intervention group (cessation consultation and pharmacotherapy ): smokers patients with pulmonary tuberculosis who are under Tb DOTS Treatment that recieve smoke cessation program consultation and
Intervention groups(Brief advice counseling): smokers patients with pulmonary tuberculosis who are under Tb DOTS Treatment that receive smoking cessation brief advice for three minute. This group w
strongly and clearly advice to quit smoking, given the benefits of cessation and linking it with their current disease status by trained physician during their TB treatment in the first visit.
Smoker Control Groups: smoker patients with pulmonary tuberculosis which are under Tb Treatment and age and sex of them are matched with intervention group. They do not receive any intervention.
Non Smoker Control Groups: Non smoker patients with pulmonary tuberculosis which are under Tb Treatment and age and sex of them are matched with intervention group. They do not receive any interventio
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: current manufactured cigarette smokers will be diagnosed with active pulmonary TB: either sputum smear-positive or smear-negative, based on classification from WHO treatment guidelines; classify under treatment Category I (new TB cases) ; patients of both sexes, aged 18 years and above; speaking the Persian language. Exclusion criteria: having extra pulmonary TB only (involving CNS, pericardium, adrenal etc) ; they have multi-drug resistant tuberculosis at diagnosis ; they are living with or newly diagnosed with HIV/AIDS ; they are active IV drug abuser ; they are classified as Category II (relapse, treatment failure, and treatment after default) or Category III (chronic TB) ;they fulfill the eligibility criteria, but unwilling to participate in the study or unable to understand the contents of the informed consent form.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tuberculosis treatment outcome. Timepoint: 2,4,6 months. Method of measurement: sputum smear. | — |
Secondary
| Measure | Time frame |
|---|---|
| Smoke cessation. Timepoint: 2-4-6 months. Method of measurement: urine cotenine test.;Immunologic response(phagocytes capacity uptake and IL-8 amount). Timepoint: 3 months. Method of measurement: flow cytometry. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMahshid Aryanpur
National Research Institute of Tuberculosis and Lung Disease
Outcome results
None listed